India's cheap weight-loss drugs could reshape global obesity fight
With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
Similar Stories
Related coverage based on topic and tags
New light shed on who benefits most from weight-loss jabs
People who carry variations in two genes linked to appetite and digestion can lose more weight when taking drugs to treat obesity, research suggests.
April 8, 2026 at 03:07 PMAmazon to stock Lilly's new weight-loss pill at US kiosks, offer same-day delivery - Reuters
Amazon to stock Lilly's new weight-loss pill at US kiosks, offer same-day delivery Reuters
April 9, 2026 at 02:45 PMWhy weight-loss jabs work better for some people than others
People who carry variations in two genes linked to appetite and digestion can lose more weight when taking drugs such as Wegovy and Mounjaro to treat obesity, research suggests.
April 10, 2026 at 02:47 PMGLP-1 weight loss, side effects linked to genetic variations - Reuters
GLP-1 weight loss, side effects linked to genetic variations Reuters
April 10, 2026 at 08:08 PMIndia's Titan hits record high on strong fourth-quarter sales - Reuters
India's Titan hits record high on strong fourth-quarter sales Reuters
April 8, 2026 at 06:33 AMIndia File: Retail investors dig in as foreign money flees - Reuters
India File: Retail investors dig in as foreign money flees Reuters
April 14, 2026 at 05:30 AM